Abstract:BackgroundInfection of SARS-CoV-2 may cause acute respiratory syndrome. It has been reported that SARS-CoV-2 nucleocapsid protein (N-protein) presents early in body fluids during infection. The direct involvement of N-protein in lung injury is poorly understood. MethodsRecombinant N-protein was pretreated with polymyxin B, a lipopolysaccharide (LPS)-neutralizing agent. C57BL/6, C3H/HeJ (resistant to LPS), and C3H/HeN (control for C3H/HeJ) mice were exposed to N-protein via intratracheal administration to examine acute lung injury. In vitro, bone marrow-derived macrophages (BMDMs) were cultured with N-protein to study phosphorylation of nuclear factor kappa B (NF-kappa B) p65, macrophage polarization, and expression of proinflammatory cytokines. ResultsN-protein produced acute lung injury in C57BL/6 mice, with elevated protein permeability, total cell count, neutrophil infiltration, and proinflammatory cytokines in the bronchioalveolar lavage. N-protein also induced lung injury in both C3H/HeJ and C3H/HeN mice, indicating that the effect could not be attributed to the LPS contamination. N-protein triggered phosphorylation of NF-kappa B p65 in vitro, which was abolished by both N-protein denaturation and treatment with an antibody for N-protein, demonstrating that the effect is N-protein specific. In addition, N-protein promoted M1 macrophage polarization and the expression of proinflammatory cytokines, which was also blocked by N-protein denaturation and antibody for N-protein. Furthermore, N-protein induced NF-kappa B p65 phosphorylation in the lung, while pyrrolidine dithiocarbamate, an NF-kappa B inhibitor, alleviated the effect of N-protein on acute lung injury. ConclusionsSARS-CoV-2 N-protein itself is toxic and induces acute lung injury in mice. Both N-protein and NF-kappa B pathway may be therapeutic targets for treating multi-organ injuries in Coronavirus disease 2019 (COVID-19).

Short and Long-Term Dynamic Voltage Instability

Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection

SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation

SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway

SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation

Human ZBP1 induces cell death‐independent inflammatory signaling via RIPK3 and RIPK1

SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation

SARS-CoV-2 N Protein Induces Acute Lung Injury in Mice <i>via</i> NF-B Activation

SARS-CoV-2 N Protein Triggers Acute Lung Injury Via Modulating Macrophage Activation and Infiltration in in Vitro and in Vivo

Inflammation and Antiviral Immune Response Associated With Severe Progression of COVID-19

An Active Matrix Flat Panel Dosimeter (AMFPD) for in-phantom dosimetric measurements.

RNA-induced Liquid Phase Separation of SARS-CoV-2 Nucleocapsid Protein Facilitates NF-κB Hyper-Activation and Inflammation.

ZBP1-dependent inflammatory cell death, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy during coronavirus infection

SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-κB

TLR2 Senses the SARS-CoV-2 Envelope Protein to Produce Inflammatory Cytokines

HIF-1α promotes SARS-CoV-2 infection and aggravates inflammatory responses to COVID-19

Interleukin-1RA Mitigates SARS-CoV-2-Induced Inflammatory Lung Vascular Leakage and Mortality in Humanized K18-hACE-2 Mice

Inflammasome activation in infected macrophages drives COVID-19 pathology

SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation

An Intervention Airing the Effect of Iranian Propolis on Epithelial Dysplasia of the Tongue: A Preliminary Study.

SARS‐CoV‐2 sensing by RIG‐I and MDA5 links epithelial infection to macrophage inflammation